Protocol Ledger

NCT04639986 · Phase III · ACTIVE NOT RECRUITING

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Interventional Phase III clinical trial protocol NCT04639986 sponsored by Gilead Sciences in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-11-23 Enrollment: 331 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04639986
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)331 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04639986
Protocol FieldVerified Registry Value
NCT IdentifierNCT04639986
Consolidated Lead SponsorGilead Sciences
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment331 participants (ACTUAL)
Registered Start Date2020-11-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04639986
Hospital Research SiteLocationSite Profile
Chinese PLA General HospitalBeijing, ChinaOpen Hospital Dossier ->
Peking University People's HospitalBeijing, ChinaOpen Hospital Dossier ->
Jilin Cancer HospitalChangchun, ChinaOpen Hospital Dossier ->
The First Hospital of Jilin UniversityChangchun, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI